Research Topics
| C W HowdenSummaryAffiliation: Northwestern University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategiesC W Howden
Northwestern University Medical School, Chicago, Illinois, USA
Am J Gastroenterol 96:1704-10. 2001..CONCLUSION: Proton pump inhibitor treatment provides more consistent heartburn relief than an H2-receptor antagonist, or "step-up" or "step-down" therapy...
Editorial: just how "difficult" is it to withdraw PPI treatment?Colin W Howden
Division of Gastroenterology, Northwestern University Feinberg School of Medicine, 676 N St Clair Street, Suite 1400, Chicago, IL 60611 2951, USA
Am J Gastroenterol 105:1538-40. 2010..However, as with all drugs, PPIs should be dosed appropriately, and should be reserved for patients with conditions for which there is clear evidence of benefit from therapy...- Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERDColin W Howden
Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL60611, USA
J Clin Gastroenterol 43:323-6. 2009..To compare the effects of immediate-release omeprazole and 2 different delayed-release proton pump inhibitors on 24-hour intragastric acidity in gastroesophageal reflux disease patients... - Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 hC W Howden
Division of Gastroenterology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Aliment Pharmacol Ther 23:975-84. 2006..Attainment of intragastric pH < 6.0 may require high-dose continuously infused proton pump therapy... - Review article: immediate-release proton-pump inhibitor therapy--potential advantagesC W Howden
Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Aliment Pharmacol Ther 22:25-30. 2005..In conclusion, immediate-release omeprazole is associated with rapid absorption of omeprazole and rapid onset of antisecretory effect, without compromising the duration of acid suppression... - Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providersN Elnachef
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA
Aliment Pharmacol Ther 28:1249-58. 2008..Our understanding of the benefits and risks of aspirin non steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) selective NSAIDs and gastro-protective agents (GPAs) continues to expand... - Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleedingC W Howden
Division of Gastroenterology and Hepatology, Northwestern University Medical School, Chicago, IL 60611, USA
Am J Health Syst Pharm 56:S5-11. 1999..pylori-negative and H. pylori-positive peptic ulcers, as well as in upper gastrointestinal tract bleeding. Further study is needed regarding their role in preventing stress ulcers in critically ill patients... - Current indications for acid suppressants in Helicobacter pylori -negative ulcer diseaseC W Howden
Northwestern University Medical School, Chicago, IL, USA
Best Pract Res Clin Gastroenterol 15:401-12. 2001..The optimal duration of treatment is undefined but might be lifelong. There are no prospective studies of the efficacy of surgery or mucosal-protective agents in the treatment of H. pylori -negative ulcers... - Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom reliefC W Howden
Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Aliment Pharmacol Ther 30:895-907. 2009..Dexlansoprazole MR, a modified-release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis... - Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitisD C Metz
University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, PA, USA
Aliment Pharmacol Ther 29:742-54. 2009..Dexlansoprazole MR heals all grades of erosive oesophagitis (EO)... - Vitamin B12 levels during prolonged treatment with proton pump inhibitorsC W Howden
Northwestern Center for Clinical Research, Northwestern University, Chicago, IL 60611, USA
J Clin Gastroenterol 30:29-33. 2000..An appreciation of normal cobalamin metabolism and the pharmacological action of the PPIs adequately explain the mechanism for this reduction. PPIs do not promote the development of pernicious anemia... - Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical centerG A Coté
Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Aliment Pharmacol Ther 25:709-14. 2007..In July 2001, our Veterans' Affairs hospital changed its formulary proton pump inhibitor (PPI) from lansoprazole to rabeprazole. All patients previously receiving lansoprazole 30 mg twice daily were switched to rabeprazole 20 mg once daily... - Differing attitudes toward virtual and conventional colonoscopy for colorectal cancer screening: surveys among primary care physicians and potential patientsT L Angtuaco
Rush-Presbyterian-St. Luke's Medical Center and Northwestern University Medical School, Chicago, Illinois, USA
Am J Gastroenterol 96:887-93. 2001..Potential patients were more encouraged than physicians by the availability of virtual colonoscopy for improving participation in colorectal cancer screening... - Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?T J Lee
Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Aliment Pharmacol Ther 20:1241-51. 2004..Proton-pump inhibitors are often recommended for continuous use in gastro-oesophageal reflux disease, but this may not be necessary in all patients... - Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national surveyW D Chey
Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
Aliment Pharmacol Ther 23:655-68. 2006..To assess primary care physician perceptions of non-steroidal anti-inflammatory drug (NSAID) and aspirin-associated toxicity... - The utility of urgent colonoscopy in the evaluation of acute lower gastrointestinal tract bleeding: a 2-year experience from a single centerT L Angtuaco
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA
Am J Gastroenterol 96:1782-5. 2001..Spontaneous resolution is frequent, length of hospital stay is similar, and clinical outcome is excellent regardless of whether or not urgent colonoscopy is performed... - Meta-analysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcerJ E Levine
Department of Medicine, Evanston Hospital, Evanston, IL, USA
Aliment Pharmacol Ther 16:1137-42. 2002..Because proton pump inhibitors have a greater inhibitory effect on gastric acid secretion than H2-receptor antagonists, they may be more effective in ulcer bleeding and should be further evaluated for that indication... - Review article: similarities and differences among delayed-release proton-pump inhibitor formulationsJ R Horn
Department of Pharmacy, University of Washington, Seattle, WA, USA
Aliment Pharmacol Ther 22:20-4. 2005..However, minor pharmacodynamic and pharmacokinetic differences are not associated with meaningful differences in clinical outcomes... - Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay--results from the Cochrane CollaborationG I Leontiadis
Division of Gastroenterology, First Department of Medicine, University of Thessaloniki School of Medicine, AHEPA Hospital, Thessaloniki, Greece
Aliment Pharmacol Ther 22:169-74. 2005..CONCLUSIONS: Proton-pump inhibitor treatment for ulcer bleeding produces small, but potentially important, reductions in transfusion requirements and length of hospitalization... - Review article: the clinical pharmacology of proton pump inhibitorsG Sachs
Department of Physiology and Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
Aliment Pharmacol Ther 23:2-8. 2006..The chemical and pharmacological characteristics of tenatoprazole give it theoretical advantages over benzimidazole-based proton pump inhibitors that should translate into improved acid control, particularly during the night... - Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux diseaseJ Pisegna
Division of Gastroenterology and Hepatology, VA Greater Los Angeles Health Care System, Los Angeles, CA 90073, USA
Aliment Pharmacol Ther 20:47-56. 2004..A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.)... - Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitisV K Sharma
University of Arkansas for Medical Sciences, Little Rock, AR, USA
Aliment Pharmacol Ther 15:227-31. 2001..CONCLUSION: Lansoprazole 30 mg produces healing rates in erosive oesophagitis that are not statistically significantly different to those of omeprazole 20 mg... - Review article: management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradicationG Holtmann
University of Essen, Department of Gastroenterology, Hufelandstr 55, D 45122, Essen, Germany
Aliment Pharmacol Ther 19:66-70. 2004..e. Helicobacter pylori infection, use of aspirin or nonsteroidal anti-inflammatory drugs). Elimination or modification of these risk factors reduces the risk of ulcer recurrence and, hence, of recurrent ulcer bleeding... - Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhageV K Sharma
Division of Digestive Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Aliment Pharmacol Ther 15:1939-47. 2001..All patients with ulcer bleeding should be tested for H. pylori infection and appropriately treated if positive... - Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia--a post hoc analysis from the Cochrane CollaborationG I Leontiadis
Department of Gastroenterology, University Hospital of North Durham, Durham, UK
Aliment Pharmacol Ther 21:1055-61. 2005..CONCLUSIONS: Proton-pump inhibitor therapy for ulcer bleeding has been more efficacious in Asia than elsewhere. This may be because of an enhanced pharmacodynamic effect of proton-pump inhibitors in Asian patients...